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Albuminuria is a risk factor strongly associated with cardiovascular disease, the first cause of 
death in the general population. It is well established that Renin-Angiotensin-System 
suppressors prevent the development of new-onset albuminuria in naïf hypertensive patients 
and diminish its excretion, but we cannot forget the percentage of hypertensive patients who 
develop de novo albuminuria. Here, we applied multiple proteomic strategy with the purpose 
to elucidate specific molecular pathways involved in the pathogenesis and provide predictors 
and chronic organ damage indicators.  
1143 patients were followed for a minimum period of 3 years. Hypertensive patients 
chronically RAS suppressed were recruited, classified in 3 different groups depending on 
their albuminuria levels (normoalbuminuria, de novo albuminuria and sustained albuminuria) 
and investigated by multiple proteomic strategy. Our strategy allowed us to perform one of 
the deepest plasma proteomic analysis so far which has shown two proteomic signatures: l) 
with predictive value of de novo albuminuria and 2) sustained albuminuria indicator proteins. 
These signatures are related to inflammation, immune as well as in the proteasome activation 
occurring in situations of endoplasmic reticulum stress. Furthermore, these results open the 
possibility of a future strategy based on anti-immune therapy to treat hypertension which 
could help to prevent the development of albuminuria and hence, the progression of kidney 
damage. 
 

























    
    
    
    
    












 Albuminuria is a risk factor strongly associated with cardiovascular and renal complications 
particularly when diabetes and hypertension are present. However, in the absence of these 
two processes albuminuria can be equally relevant as a predictor.1 These facts reflect the 
enormous relevance of albuminuria to monitor cardiovascular disease (CVD), the first cause 
of death in the general population.2 Different factors promote the development of 
albuminuria3 and lead finally to an increased albumin leakage through the glomerular 
barrier.4-7  
Renin-Angiotensin- System (RAS) suppression is considered the therapy of choice to prevent 
the development of new-onset albuminuria in naïf patients8,9 and to diminish the amount 
excreted albuminuria.10 The positive effect depends on a reduction in blood pressure (BP),11 
as well as a modification of intraglomerular hemodynamics and permeability.12 Recent 
studies conducted by our group have shown that despite an apparently adequate RAS 
suppression, a relevant percentage of hypertensive patients develop de novo albuminuria 
pointing to a progression of CVD probably facilitated by an inappropriate therapeutic 
response to ACEi or ARB.13  
Moreover, we have also found an increased systemic oxidative damage in hypertensive 
patients who dev lop albuminuria under chronic RAS suppression suggesting that oxidative 
stress is one of the mechanisms underlying the development of albuminuria14 in this situation. 
These considerations highlight the need to continue searching for potential mechanisms and 
indicators of the development and progression of albuminuria in hypertensive patients under 
RAS suppression, considering that it will contribute to better understand the pathogenesis of 
the progression of CV and renal disease under chronic treatment with either an ACEi or an 






















    
    
    
    
    











Recently, substantial improvements in the entire MS-based proteomics pipeline, including 
sample preparation, liquid chromatography mass spectrometry hardware and data analysis, 
have been produced. In this study, we present the application of an –omics strategy to 
approach the unbiased, non-targeted, study of albuminuria in hypertensive patients with RAS 
blockade searching for predictors and chronic organ damage markers in blood plasma (Figure 
1A).  
Our data show the existence of 2 characteristic plasma protein signatures described for the 
first time consisting of: 1) protein candidates to be markers of de novo albuminuria, 
composed by 4 proteins and 2) sustained albuminuria indicator proteins, made up of 16 
proteins, which may be considered markers of end organ damage. The proteins hereby 
associated with albuminuria development point to the activation of the immune system, as 
well as inflammation and endoplasmic reticulum stress (ERS), which might be related to the 




Patient selection and classification was previously described in an initial paper showing the 
development of albuminuria in patients during chronic RAS suppression.13 Briefly; 1143 
patients were followed for a minimum period of three years with visits to the Hypertension 
Unit, Hospital Universitario 12 de Octubre, Madrid, at least, every 6 months. After that, the 
patients continued with their annual revisions. One hundred twenty nine hypertensive patients 
chronically RAS suppressed with or without high albuminuria (48 diabetics and 81 non-
diabetics, HTA RAS patients) were recruited between January 2011 and June 2013 in the 






















    
    
    
    
    











Albuminuria is defined as albumin/creatinine ratio (ACR) in the urine greater than 20 mg/24 
h and 30 mg/24 h in men and women, respectively.  
For the discovery phase, 24 HTA RAS patients were classified based on ACR in urine and 
development time of albuminuria in three groups: a) normoalbuminuric patients (N); b) de 
novo albuminuria (dnA), patients who developed de novo albuminuria in the last ten years 
and c) patients with sustained albuminuria (SA) at baseline, which maintained elevated 
albuminuria levels during follow-up. Then, we confirmed these proteins in a cohort of 
patients with or without diabetes with the objective of verifying our findings in a general 
population. All the patients were matched by baseline characteristics and medications (Table 
S4).  
In the validation phase, 105 patients were classified in the same groups as previously 
described. The clinical characteristics and medications of these hypertensive patients are 
shown in Table 2. A significant decrease of Estimated Glomerular Filtration Rate (eGFR) 
(ANOVA, p = 0.004) was observed fo  both albuminuric groups (dnA and SA), which 
implies impaired renal function associated with kidney damage.  
The study was conducted according to the recommendations of the Declaration of Helsinki 
and was approved by the “Hospital 12 de Octubre” ethics committee. In all cases informed 
consent was requested from subjects indicating that their participation in the study was not 
prejudicial in any way to the treatment and possessed no risk.  
Proteomics pipeline 
The experimental strategy consisted in: 1) an immunodepletion of the 14 more abundant 
plasma proteins, 2) a discovery phase using two different, complementary and robust 
proteomics techniques, 2D-DIGE (GE-Healthcare) and iTRAQ labeling (AB Sciex) followed 






















    
    
    
    
    











in an independent cohort of patients by Selected Reaction Monitoring (SRM) analysis18. See 
details in supplementary material.  
For 2D-DIGE and iTRAQ experiments, we employed 24 plasma samples (n = 8, per group), 
which were combined to generate four sample pools per group (N1-N4, dnA1-dnA4 and 
SA1-SA4) (Tables S2 and S3). In the SRM assay, we grouped the 105 plasma samples (N = 
53, dnA = 26 and SA = 26) into 32 pools (N1-N15, dnA1-dnA9 and SA1-SA8). The pool 
samples were perfectly grouped taking into account their clinical characteristics and 
albuminuria levels. 
Statistical methods 
Values for patients' characteristics are expressed as means ± standard deviation (SD) or 
percentages. For all comparisons, one-way ANOVA was used to calculate statistically 
significant differences of the values between the different groups studied. Post-hoc analysis 
of significant ANOVA results was performed by means of Tukey analysis. In iTRAQ results, 
we have considered differentially expressed those proteins identified with at least two 
peptides and log2-ratios expressed in form of the standardized variables (Zq) ± 2 with p 
values ≤ 0.05, being Zq the mean for the 4 replicates versus the  normoalbuminuria group. In 
relation to 2D-DIGE analysis, we selected significant protein spots with a 1.3-fold difference 
in abundance between groups. For SRM, we have considered significant those peptides 
showing significant differences in at least two of the three analyzed transitions. In all cases, 
we have represented the transition of the most significant peptide. Receiver operating 
characteristic (ROC) curves were generated using SPSS 15.0 for windows software (SPSS 























    
    
    
    
    












In this work, we investigated molecular changes involved in the development of albuminuria 
in the plasma proteome of hypertensive patients with RAS suppression using different 
proteomics approaches (iTRAQ and 2D-DIGE). On the one hand, the use of an iTRAQ LC-
MS/MS strategy has allowed us to perform one of the deepest plasma proteomic analyses so 
far, which led us to identify 4935 proteins, 36 differentially expressed (Table S1). On the 
other hand, the 2D-DIGE analysis allows us to identify 12 differentially expressed proteins 
(Table S2 and Figure S1), which did not significantly expressed by iTRAQ. The combination 
of these two different and complementary proteomics techniques, in the discovery phase, 
guarantees a more extensive coverage of quantified proteins. Our results allowed us to 
describe 5 differential proteins that had never been before detected in plasma/serum; NALP9, 
UBP47, DNJC9, ORNT1 and CHADL, according to Uniprot and The human protein atlas 
databases, and therefore low abundance proteins could be quantified by the hereby presented 
mass spectrometry-based strategy. In order to validate these alterations, 39 proteins were 
analyzed by SRM assay; the whole proteins found significantly expressed by 2D-DIGE and 
27 proteins selected among the total varied in iTRAQ analysis, taking into account the fold 
change and their implication in molecular mechanisms related to the pathology. A total of 17 
proteins were validated by SRM in an independent cohort of 105 subjects (Figure 2A and 
Table S3). Confirmed altered proteins were classified according to their biological functions 
(Table 1), as we said before. Besides, these proteins were analyzed employing ROC curves, a 
useful tool, which allow us to discriminate the different groups of study attending to their 
protein expression levels. We performed a principal component analysis (PCA) with the 
whole of differentially expressed proteins validated (Figure 2B), which showed a correct 
grouping of patients with sustained albuminuria respect to the other two groups (Figure 2C). 






















    
    
    
    
    











albuminuria, which are formed by 4 out of the 17 proteins validates by SRM, and the second 
one, may be considered markers of end organ damage since their levels are altered in 
sustained albuminuric patients and made up of 16 proteins (3 already varied in dnA) (Figure 
2C). 
 
Plasma proteomic signature with predictive value of de novo albuminuria: SRM results 
have shown the up-regulation of 3 proteins involved in immune response: CFAB, IGKC, 
IGHA2 (Figure 4A) and a decrease in HEMO (Figure 3D). ROC curve for these 4 proteins 
showed a significant classification value (p = 0.003) of this panel for the separation of dnA 
patients with respect to N, with a considerably high AUC of 0.874 (Figure 4A). 
Panel of protein markers of sustained albuminuria: SRM results have shown a total of 5 
up-regulated plasma proteins involved in immune response (IGKC, LV302, IGHA2, IGHG2 
and IGHG3) (Figure 3A), among which two of them (IGKC and IGHA2) were found 
previously altered in sustained albuminuria. In addition, 5 altered proteins related with 
inflammation (A2GL, PON1, SAMP, NALP9 and HEMO) (Figure 3B), 2 involved in 
endoplasmic reticulum stress (UBP47 and DNJC9) (Figure 3C) and other 4 proteins with 
different functions such as vitamin D transport, blood coagulation, urea cycle and 
chondrocyte differentiation (VTDB, ORNT1, F13B and CHADL, respectively) were found 
altered in sustained albuminuric patients (SA) (Figure 3D). Moreover, ROC curves have 
shown a good sensitivity and specificity (AUC =1) indicating that these panels of proteins 
could discriminate sustained albuminuric patients from normoalbuminurics with a significant 























    
    
    
    
    











Over the past 20 years the proteomic evolution has included a better understanding of the 
need to consider cardiovascular proteomics that resolve, identify and elucidate cardiovascular 
disease process.19 Regarding this, we performed 2 complementary proteomic approaches to 
analyze plasma in order to search for potential indicators for an adequate risk assessment in 
hypertensive patients under chronic RAS suppression. With this purpose, we analyzed 3 
groups of patients: N, dnA and SA with a different response to RAS suppression, therefore 
exploring underlying mechanisms of albuminuria development associated to inefficient 
therapeutic response. We have found a total number of 48 differentially expressed proteins, 
of which 17 were subsequently confirmed by SRM in an independent cohort of 105 patients. 
The proteomic alterations observed has allowed us to molecularly characterize several 
processes involved in albuminuria development and hence associated with cardio-renal risk 
(Figure 5).  
The great majority of these 17 proteins are involved in immune response, inflammation and 
ERS, pointing to the activation of these processes in albuminuric patients. Moreover ROC 
curves, of great utility for evaluating diagnostic tests, have shown good sensitivity and 
selectivity for these protein markers, which prove the potential value of these indicators to 
classify hypertensive patients according to albuminuria onset.  
A panel of 4 proteins (CFAB, IGKC, IGHA2 and HEMO) has shown alterations in plasma 
levels from patients who developed de novo albuminuria, compared to those remaining 
normoalbuminurics. Therefore, these proteins might have a potential predictive value for the 
development of albuminuria, which is furthermore enhanced by the ROC curve comparing 
dnA vs. N (Figure 4A). CFAB, a component of innate response, is the only protein that 
exclusively appears in the group of de novo albuminuria and its basal levels are subsequently 






















    
    
    
    
    











immunity is activated in early stages of hypertension and end-organ damage.20 Similar 
findings have been described in different types of renal disease.21,22 Analogous mechanisms 
may account for the observed increase of CFAB in plasma from de novo albuminuric 
patients.  
On the other hand, we have found a different proteomic signature made up of 16 proteins, 
indicators of sustained albuminuria, whose levels may be related to persistent chronic organ 
damage. It is important to note that 3 out of these 16 proteins were already found altered in 
dnA patients (IGKC, IGHA2 and HEMO). These data show the augment of 2 
immunoglobulins at an earlier stage of the pathogenesis which remained altered in more 
advanced stages, indicating that their up-regulation persists after the development of 
albuminuria. In total, we found higher levels of 5 immunoglobulins in the albuminuric 
patients, which could reflect intraglomerular inflammatory conditions contributing to an 
increase in glomerular permeability allowing the passage of albumin into the urine in such (a 
significant decrease of eGFR in patients is shown in Table 2). Similar increases in 
permeability should be taking place simultaneously in systemic vasculature.23 A greater 
activation of this immune response involving LV302, IGHG2 and IGHG3 is observed and 
probably participates in albuminuria persistence. In fact, previous studies with chronic kidney 
disease are lined with our results describing an activation of immune cells associated with 
impaired renal function in such patients.24 In addition, serum free light chains (FLCs) such as 
IGKC and LV302 have been associated with renal failure due to its accumulation in plasma 
as a result of inefficient clearing by the kidneys leading to GFR decrease.25 Furthermore, the 
immune system plays a critical role in modulating renal injury through activation of 






















    
    
    
    
    











Even more, a subset of 5 proteins (A2GL, SAMP, NALP9, HEMO, and PON1) related with 
inflammation processes has also been found altered in patients with sustained albuminuria, 
which seems related to the presence of persistent renal damage inferred by the observed 
significant decrease of eGFR (Table 2). These findings may suggest that, while kidney 
damage progresses, an enhanced inflammatory process is triggered leading to an alteration of 
the levels of these proteins observed in plasma that simultaneously contribute to progression 
of systemic atherosclerosis.27-30 In addition, HEMO plays an important antioxidant role31,32 
and a decrease of this protein could participate worsening the endothelial dysfunction present 
in these patients, therefore increasing cardiovascular risk and renal damage. In fact, our 
previous studies showing an increased oxidative damage in albuminuric patients support this 
finding.14 
Another group consisting of two proteins (UBP47 and DNJC9) has been involved in the 
proteasome activation in situations of endoplasmic reticulum stress (ERS). In the progression 
of CKD, albumin overload leads to ERS in the kidney, which has been associated with 
apoptosis of proximal tubular cells.33 A defective proximal reabsorption of albumin can be 
invoked and explained through this proximal tubular damage.34 Altered levels of UBP47and 
DNJC9 in SA patients point to the activation of a defense mechanism to counteract ERS, 
responsible for the degradation of misfolded proteins by the proteasome. In fact, DNJC9, 
which appears up-regulated in SA, is involved in the ubiquitination tagging of misfolded 
proteins driving their degradation by the proteasome, while UBP47 is a deubiquitinase, 
therefore conducting the opposite process to that of DNJC9, whose decrease favors as well 
proteasome-mediated degradation. The activation of the ubiquitination-proteasome system 
(UPS) may not be able to compensate ERS, which has been shown to lead to glomerular 






















    
    
    
    
    











stress conditions.35 ROC curve for UBP47 and DNJC9 has shown a perfect classification of 
SA with an AUC of 1 (Figure 4 B3), and considering that these proteins had never been 
before detected in plasma, this result points to a great potential of these 2 novel plasma 
proteins for monitoring renal function in hypertensive patients.  
The hereby reported results show that hypertensive subjects who develop albuminuria under 
chronic RAS suppression exhibit an early activation of the immune response reflected by the 
increase of 2 immunoglobulins (IGHA2 and IGKC).With the evolution to sustained 
albuminuria, a greater immune activation is observed, since elevated levels of these 2 
immunoglobulins together with 3 more: IGHG2, IGHG3 and LV302 were detected, which 
might be involved in the progressive renal damage observed. In addition, ROC curve value 
for this subset of immunoglobulins showed a correct classification of sustained albuminuric 
patients with respect to normoalbuminurics. 
In this sense, our results are in line with previous studies pointing to a determinant role of the 
immune response in the pathogenesis of hypertension36 and also provide additional molecular 
data showing particular immunoglobulins altered with albuminuria. Thus, the up-regulation 
of proteins involved in the immune system in patients with albuminuria could elucidate 
specific molecular pathways involved in the pathogenesis of organ damage, as well as 
support a hypothesis with increasing approval in the scientific community pointing to the 
great potential of a future strategy based on anti-immune therapy to treat hypertension.37 In 
fact, hypertensive rats treated with this therapy showed increased GFR, decreased urinary 
protein excretion,38 as well as reduced blood pressure, inflammation and ROS39 which 























    
    
    
    
    











In this work we show the great potential of plasma proteomics to discover novel indicators of 
early albuminuria and end-organ damage in hypertensive patients under RAS suppression and 
provide new proteins present in plasma together with a subset of promising markers of 
albuminuria to the high AUC values observed. Some limitations of our study are the use of 
pools for the proteomic analysis and the necessity to increase the number of patients in order 
to confirm the potential value of the hereby described protein indicators. Moreover, a 
prospective study will be required to determine the clinical utility of these proteins as 
potential biomarkers which could allow distinguishing two stages in the evolution of 
albuminuric patients chronically RAS suppressed. Strategies to stimulate reverse translation 
from clinical observations to the bench and to better merge clinical and basic science projects 
to facilitate translation are also needed.19 
PERSPECTIVES 
Our goal was identified molecular signatures able to elucidate specific molecular pathways 
involved in the pathogenesis and may provide predictors and chronic organ damage 
indicators in albuminuric patients during chronic renin-angiotensin suppression. More 
importantly, proposed markers allow early identification of patients at cardiovascular risk 
when clinical predic ors as albuminuria are still in the normal range and this makes possible 
to adapt, better and earlier, the pharmacological intervention for those individuals at higher 
risk. According to these considerations, the key point of our study is that we provide the 
discovery of 2 different protein profiles which could allow distinguishing two stages in the 
evolution of albuminuric patients. Furthermore, these results open the possibility of a future 
strategy based on anti-immune therapy to treat hypertension which could help to prevent the 
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Novelty and Significance:  
1) What Is New 
The combination of two complementary proteomic approaches to analyze plasma has 
identified new potential predictors of renal damage and de novo albuminuria indicators. 
These protein signatures could allow us to monitor albuminuria in hypertensive patients with 
suppression of renin angiotensin system. 
 
2) What Is Relevant? 
The main question is that evolution of hypertensive patients who are chronically treated to 
control blood pressure is unpredictable in terms of albuminuria development. Thus, this is a 
clinical question of extreme importance and there are no current studies on it apart from 
previous research from our group14,15,16.  The proteomic analysis has allowed identifying two 
proteomic signatures involved in the development of de novo and sustained albuminuria, which are 
related to inflammation, immune response and endoplasmic reticulum stress. The relevance of our 
findings is that this strategy may contribute to adequate risk assessement and earlier intervention and 
better outcome of these patients.  
 
 Summary 
High prevalence of albuminuria in patients chronically RAAS suppressed has been 
demonstrated, and currently there are no available markers able to predict evolution of these 
chronically treated patients. Our strategy allowed us to perform one of the deepest plasma 
proteomic analysis so far which has shown two proteomic signatures: l) with predictive value 






















    
    
    
    
    












FIGURE 1:- (A) Experimental design based on –omics strategy to approach the unbiased, 
non-targeted study of albuminuria in hypertensive patients searching for predictors and 
chronic organ damage markers in blood plasma. (B) Schematic representation of the clinical 
monitoring of the 1433 patients during 3 years in the Hypertension Unit of Hospital 12 de 
Octubre, Madrid, Spain. The protocol includes a baseline study followed by 3 month period 
of stabilization. Patients were subsequently followed during 3 years with visits to the unit 
every 6 months. The proteomics analysis started at the end of this period. 
 
FIGURE 2:- A) Schematic picture of differentially expressed proteins identified by 2D-
DIGE and iTRAQ and those validated by SRM. B) Principal component analysis where 
different groups were separated based on the 17 differentially expressed proteins validated by 
SRM. C) Two different plasma signatures, one of de novo albuminuria and the second of 
sustained high albuminuria are shown. N: normoalbuminuria; dnA: de novo albuminuria; SA: 
sustained albuminuria.  
FIGURE 3:- Validation of 17 proteins by Selected Reaction Monitoring (SRM). A) Panel of 
proteins related with immune response. B) Proteins involved in inflammation. C) Proteins 
related with endoplasmic reticulum stress. D) Proteins with other functions. In the bar charts, 
we have represented the transition of the most significant peptide. N: normoalbuminuria; 
dnA: de novo albuminuria; SA: sustained albuminuria. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001, # p = 0.051. 
FIGURE 4:- Receiver Operating Characteristic (ROC) curves for classification of patients 
with de novo and sustained albuminuria vs normoalbuminurics. A) Proteins with predictive 






















    
    
    
    
    











immune system (B1), inflammation (B2), endoplasmic reticulum stress (B3) and proteins 
involved in other functions (B4). Area under the ROC curve (AUC) with 95% confidence 
intervals was calculated and p-value ≤ 0.05 was considered statistically significant. N: 
normoalbuminuria; dnA: de novo albuminuria; SA: sustained albuminuria.  
FIGURE 5:- The activation immune system in hypertensive patients with high albuminuria 
under chronic RAS suppression. Mechanisms involved in the pathogenesis of renal damage 
and functional implication of observed protein alterations related with immune response, 
inflammation and apoptosis. The immune-suppression as future therapy could prevent the 
































Table 1. Biological functions of 17 proteins validated by SRM 
Protein name Abbreviation Function   P-value   
dnA/N SA/N SA/dnA 
Ig gamma-3 chain C IGHG3 Immune system response  ↑ 0.005 ↑ 0.008 
Ig gamma-2 chain C IGHG2 Immune system response  ↑ 9.29 • 10-5 ↑ 0.014 
Ig alpha-2 chain C IGHA2 Immune system response ↑  0.028 ↑ 3.14 • 10-4  
Ig kappa chain C IGKC Immune system response ↑  0.014 ↑ 0.008  
Ubiquitin carboxyl-terminal hydrolase 47 UBP47 Apoptosis  ↓ 6.17 • 10-8 ↓ 2.5 • 10-5 
NACHT. LRR and PYD domains-containing protein 9 NALP9 Inflammation  ↑ 4.6 • 10-4 ↑ 0.002 
Dna J homolog subfamily C member 9 DNJC9 Apoptosis   ↑ 5.87 • 10-6 ↑ 4.24 • 10-6 
Chondroadherin-likeprotein CHADL Chondrocyte 
differentiation 
 ↓ 0.003 ↓ 0.002 
Ig lambda chain V-III region LOI  LV302 Immune system response  ↑ 0.020  
Mitochondrial ornithine transporter 1 ORNT1 Metabolic process  ↑ 0.020 
Vitamin D-binding protein VTDB Lipid binding  ↑ 1.62 • 10-6 ↑ 1.09 • 10-5 
Complement factor B CFAB Immune system response ↑ 0.012   
Coagulation factor XIII B chain F13B Coagulation  ↓ 6.2.19 • 10-6 ↓ 0.003 
Hemopexin HEMO Inflammation ↓ 0.051 ↓ 0.040  
Leucine-rich alpha-2-glycoprotein A2GL Inflammation  ↑ 0.001 ↑ 8.23 • 10-5 
Serum paraoxonase/arylesterase 1 PON1 Inflammation  ↑ 4.31 • 10-7 ↑ 1.13 • 10-5 
Serum amyloid P-component SAMP Inflammation  ↑ 0.002 ↑ 0.001 


























    
    
    
    
    











Table 2. Demographic data and clinical characteristics of the study population recruited for 
 the validation phase 





Age (years) 64 ± 11 69 ± 8 66 ± 11 0.264 
Male sex (%) 40 70 70 0.005* 
BMI (kg/m2) 30 ± 4 30 ± 5 30 ± 4 0.966 
Current smoking (%) 9 15 11 0.743 
Albumin/creatinine (mg/g) 7.61 ± 
6,67 
116 ± 126 371 ± 573 0.000006
† 
Creatinine clearance rate 
(mg/mL) 
165 ± 38 87 ± 48 80 ± 39 0.405 
eGFR (ml/min/1.73m2) 81 ± 17 68 ± 20 67 ± 26 0.004* 
Total cholesterol (mg/dL) 186 ± 29 166 ± 26 168 ± 26 0.003* 
Triglycerides (mg/dL) 123 ± 50 137 ± 36 131 ± 71 0.583 
HDL cholesterol (mg/dL) 55 ± 12 50 ± 10 47 ± 13 0.018* 
LDL cholesterol (mg/dL) 106 ± 27 89 ± 19 97 ± 18 0.010* 
Glycaemia (mg/dL) 118 ± 40 127 ± 26 118 ± 33 0.583 
Uricacid (mg/dL) 5 ± 2 6 ± 2 7 ± 2 0.000* 
Systolicbloodpressure (mmHg) 139 ± 18 136 ± 20 141 ± 28 0.663 
Diastolicbloodpressure (mmHg) 82 ± 11 80 ± 10 83 ± 14 0.761 
Diabetes (%) 38 62 54 0.107 
ACEi (%) 17 23 23 0,737 
ARB (%) 77 73 70 0,73 
Diuretic (%) 23 35 54 0.022* 
Calciumchannelblocker (%) 47 46 61 0.428 
Beta blockingagent (%) 26 35 27 0.733 
Alphablockingagent (%) 17 35 19 0.191 
Anticoagulantagent (%) 40 50 31 0.366 
Lipidloweringagents (%) 74 69 81 0.627 
Antidiabeticagent (%) 26 42 38 0.302 
 
Values expressed as mean ± SD or percentages (%). BMI: body mass index; eGFR: estimated 
glomerular filtration rate; HDL: high-density lipoprotein cholesterol; LDL: low-density 
lipoprotein cholesterol; ACEi: angiotensin converting enzyme inhibitors; ARB: angiotensin 
receptor blockers. N: normoalbuminuria; dnA: de novo albuminuria; SA: sustained albuminuria. 
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